全文获取类型
收费全文 | 142392篇 |
免费 | 45123篇 |
国内免费 | 1374篇 |
专业分类
耳鼻咽喉 | 1998篇 |
儿科学 | 5794篇 |
妇产科学 | 930篇 |
基础医学 | 28409篇 |
口腔科学 | 7404篇 |
临床医学 | 17122篇 |
内科学 | 30226篇 |
皮肤病学 | 5399篇 |
神经病学 | 19363篇 |
特种医学 | 6585篇 |
外国民族医学 | 6篇 |
外科学 | 16554篇 |
综合类 | 5612篇 |
现状与发展 | 3篇 |
一般理论 | 8篇 |
预防医学 | 9749篇 |
眼科学 | 1724篇 |
药学 | 15356篇 |
13篇 | |
中国医学 | 2792篇 |
肿瘤学 | 13842篇 |
出版年
2024年 | 67篇 |
2023年 | 340篇 |
2022年 | 774篇 |
2021年 | 2440篇 |
2020年 | 6748篇 |
2019年 | 11996篇 |
2018年 | 11597篇 |
2017年 | 12895篇 |
2016年 | 11996篇 |
2015年 | 11941篇 |
2014年 | 12489篇 |
2013年 | 12700篇 |
2012年 | 11933篇 |
2011年 | 12148篇 |
2010年 | 10562篇 |
2009年 | 6893篇 |
2008年 | 7572篇 |
2007年 | 6079篇 |
2006年 | 5676篇 |
2005年 | 5541篇 |
2004年 | 5094篇 |
2003年 | 4734篇 |
2002年 | 4353篇 |
2001年 | 3490篇 |
2000年 | 2253篇 |
1999年 | 1059篇 |
1998年 | 814篇 |
1997年 | 735篇 |
1996年 | 582篇 |
1995年 | 601篇 |
1994年 | 532篇 |
1993年 | 384篇 |
1992年 | 346篇 |
1991年 | 250篇 |
1990年 | 172篇 |
1989年 | 120篇 |
1988年 | 105篇 |
1987年 | 104篇 |
1986年 | 82篇 |
1985年 | 107篇 |
1984年 | 106篇 |
1983年 | 84篇 |
1982年 | 81篇 |
1981年 | 78篇 |
1980年 | 52篇 |
1979年 | 44篇 |
1978年 | 25篇 |
1977年 | 41篇 |
1976年 | 33篇 |
1973年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 24 毫秒
31.
32.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
33.
34.
Peng‐fei Lei Shi‐long Su Ling‐yu Kong Cheng‐gong Wang Da Zhong Yi‐he Hu 《Orthopaedic Surgery》2019,11(5):914-920
Three‐dimensional (3D) printing technology, virtual reality, and augmented reality technology have been used to help surgeons to complete complex total hip arthroplasty, while their respective shortcomings limit their further application. With the development of technology, mixed reality (MR) technology has been applied to improve the success rate of complicated hip arthroplasty because of its unique advantages. We presented a case of a 59‐year‐old man with an intertrochanteric fracture in the left femur, who had received a prior left hip fusion. After admission to our hospital, a left total hip arthroplasty was performed on the patient using a combination of MR technology and 3D printing technology. Before surgery, 3D reconstruction of a certain bony landmark exposed in the surgical area was first performed. Then a veneer part was designed according to the bony landmark and connected to a reference registration landmark outside the body through a connecting rod. After that, the series of parts were made into a holistic reference registration instrument using 3D printing technology, and the patient's data for bone and surrounding tissue, along with digital 3D information of the reference registration instrument, were imported into the head‐mounted display (HMD). During the operation, the disinfected reference registration instrument was installed on the selected bony landmark, and then the automatic real‐time registration was realized by HMD through recognizing the registration landmark on the reference registration instrument, whereby the patient's virtual bone and other anatomical structures were quickly and accurately superimposed on the real body of the patient. To the best of our knowledge, this is the first report to use MR combined with 3D printing technology in total hip arthroplasty. 相似文献
35.
36.
Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features 下载免费PDF全文
37.
目的探讨酪氨酸激酶受体RON及上皮型钙粘蛋白(E-cadherin)在子宫内膜异位症(endometriosis,EMs)上的表达及意义。方法选择2017年7~12月深圳市龙岗区人民医院收治的42例EMs患者,术中分别留取新鲜异位内膜组织和在位内膜组织,随机选取子宫切除或诊断性刮宫治疗的非EMs患者42例,术中留取其正常子宫内膜组织。采用逆转录聚合酶链反应(RT-PCR)检测子宫内膜组织中RON mRNA的表达,采用免疫组织化学方法检测对应42例石蜡组织中RON蛋白和E-cadherin的表达,并分析RON蛋白和E-cadherin的相关性。结果EMs异位内膜组织RON mRNA及RON蛋白阳性表达率显著高于在位内膜组织及正常子宫内膜组织(P<0.001),在位内膜组织及正常内膜组织中E-cadherin阳性表达率显著高于异位内膜组织(P<0.001),且异位内膜组织中RON mRNA及RON蛋白的表达与临床分期有关(P<0.001)。在同一标本中RON蛋白和E-cadherin表达呈负相关关系(r=-0.497,P<0.05)。结论RON的过度表达与EMs的发生发展密切相关,联合检测RON和E-cadherin的异常对判断EMs的发生发展有一定的参考价值,RON可能成为诊断治疗EMs的新靶点。 相似文献
38.
39.
Assessment of Myocardial Infarct Size by Three‐Dimensional and Two‐Dimensional Speckle Tracking Echocardiography: A Comparative Study to Single Photon Emission Computed Tomography 下载免费PDF全文
40.